Les formes moléculaires du PSA

25 avril 2007

Auteurs : Aminé Benchikh El Fegoun, Arnauld Villers
Référence : Prog Urol, 2007, 2, 17, 165-171




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



References



Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatie cancer : assay of the complex improves clinical sensitivity for cancer Cancer Res. 1991 ;  51 : 222-226
Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., et al. Use of the percentage of free prostatespecific antigen to enhance differentiation of prostate cancer from benign prostatie disease: a prospective multicenter clinical trial Jama 1998 ;  279 : 1542-1547 [cross-ref]
Djavan B., Remzi M., Zlotta A.R., Ravery V., Hammerer P., Reissigl A., et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen : results of the prospective multicenter European trial Urology 2002 ;  60 : 4-9 [inter-ref]
Partin A.W., Brawer M.K., Bartsch G., Horninger W., Taneja S.S., Lepor H., et al. Complexed prostate specifie antigen improves specificity for prostate cancer detection : results of a prospective multicenter clinical trial J. Urol. 2003 ;  170 : 1787-1791 [cross-ref]
Roddam A.W., Duffy M.J., Hamdy F.C., Ward A.M., Patnick J., Price C.P., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml : systematic review and meta-analysis Eur. Urol. 2005 ;  48 : 386-399 [cross-ref]
Roehl K.A., Antenor J.A., Catalona W.J. Robustness of free prostate specifie antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range J. Urol. 2002 ;  168 : 922-925 [cross-ref]
Raaijmakers R., Blijenberg B.G., Finlay J.A., Rittenhouse H.G., Wildhagen M.F., Roobol M.J., et al. Prostate cancer detection in the prostate specifie antigen range of 2.0 to 3.9 ng/ml : value of percent free prostate specifie antigen on tumor detection and tumor aggressiveness J. Urol. 2004 ;  171 : 2245-2249 [cross-ref]
Van Cangh P.J., De Nayer P., De Vischer L., Sauvage P., Tombal B., Lorge F., et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA Urology 1996 ;  48 : 67-70 [inter-ref]
Canto E.I., Singh H., Shariat S.F., Kadmon D., Miles B.J., Wheeler T.M., et al. Effects of systematic 12-core biopsy on the performance of percent free prostate specifie antigen for prostate cancer detection J. Urol. 2004 ;  172 : 900-904 [cross-ref]
Davera D.I. Quel avenir pour les marqueurs tumoraux sériques ? Mise à jour des systèmes et techniques de dosage Spectra Biologie 1999 ; 28-38
Stephan C., Lein M., Jung K., Schnorr D., Loening S.A. The influence of prostate volume on the ratio of free to total prostate specifie antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia Cancer 1997 ;  79 : 104-109 [cross-ref]
Sokoll L.J., Bruzek D.J., Dua R., Dunn W., Mohr P., Wallerson G., et al. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen Urology 2002 ;  60 : 24-30 [inter-ref]
Oberpenning F., Weining C., Brandt B., De Angelis G., Heinecke A., Hamm M., et al. Combining free and total prostate specifie antigen assays from different manufacturer : the pitfalls Eur. Urol 2002 ;  42 : 577-582 [cross-ref]
Aus G., Becker C., Franzen S., Lilja H., Lodding P., Hugosson J. Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specifie antigen ratio Eur. Urol. 2004 ;  45 : 160-165 [cross-ref]
Catalona W.J., Southwick P.C., Slawin K.M., Partin A.W., Brawer M.K., Flanigan R.C., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging Urology 2000 ;  56 : 255-260 [inter-ref]
Melchior S.W., Noteboom J., Gillitzer R., Lange P.H., Blumenstein B.A., Vessella R.L. The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy BJU Int. 2001 ;  88 : 221-225 [cross-ref]
Tombal B., Querton M., De Nayer P., Sauvage P., Cosyns J.P., Feyaerts A., et al. Free/total PSA ratio does not improve prediction of pathologie stage and biochemical recurrence after radical prostatectomy Urology 2002 ;  59 : 256-260 [inter-ref]
Naya Y., Fritsche H.A., Cheli C.D., Stamey T.A., Bartsch G., Brawer M.K., et al. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer Urology 2003 ;  62 : 1058-1062 [inter-ref]
Tornblom M., Norming U., Becker C., Lilja H., Gustafsson O. Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level BJU Int. 2001 ;  87 : 638-642 [cross-ref]
Gretzenberg RH. : Advances in biomarkers for prostate diseases. In : G. Murphy SK, Partin A., Denis L., editor. Prostate Cancer 4th Edition International consultation on prostate diseases. 4th ed. Paris : Resnick MI. et al.; 2005.
Villers A., Chautard D. PSA libre: l’utilisation en routine est prematuree pour le depistage du cancer de la prostate Prog Urol. 2000 ;  10 : 618-621
Ravery C.D., Villers A., Lefranc D., Boccon-Gibod L. Complexed PSA For Early Detection Of Prostate Cancer : A Multi Institutional Study J. Urol. 2004 ; Abstract.
Parsons J.K., Partin A.W. Applying complexed prostate-specific antigen to clinical practice Urology 2004 ;  63 : 815-818 [inter-ref]
Sozen S., Eskicorapci S., Kupeli B., Irkilata L., Altinel M., Ozer G., et al. Complexed prostate specifie antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml : results of a prospective multicenter study Eur. Urol. 2005 ;  47 : 302-307 [cross-ref]
Lein M., kwiatkowski M., Semjonow A, Luboldth J., Hammerer P., Stephan C., et al. A multicenter clinical trial on the use of complexed prostate specifie antigen in low prostate specifie antigen concentrations J. Urol. 2003 ;  170 : 1175-1179 [cross-ref]
Horninger W., Cheli C.D., Babaian R.J., Fritsche H.A., Lepor H., Taneja S.S., et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter Urology 2002 ;  60 : 31-35 [inter-ref]
Allard W.J., Cheli C.D., Morris D.L., Goldblatt J., Pierre Y., Kish L., et al. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay Int. J. Biol. Markers 1999 ;  14 : 73-83
Balk S.P., Ko Y.J., Bubley G.J. Biology of prostate-specific antigen J. Clin. Oncol. 2003 ;  21 : 383-391 [cross-ref]
Catalona W.J., Bartsch G., Rittenhouse H.G., Evans C.L., Linton H.J., Amirkhan A., et al. Serum pro prostate specifie antigen improves cancer detection compared to free and complexed prostate specifie antigen in men with prostate specifie antigen 2 to 4 ng/ml J. Urol. 2003 ;  170 : 2181-2185 [cross-ref]
Lein M., Semjonow A., Graefen M., Kwiatkowski M., Abramjuk C., Stephan C., et al. A multicenter clinical trial on the use of (-5,-7) pro prostate specifie antigen J. Urol. 2005 ;  174 : 2150-2153 [cross-ref]
Nurmikko P., Pettersson K., Piironen T., Hugosson J., Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internai cleavage site at Lysl45-Lysl46 Clin. Chem. 2001 ;  47 : 1415-1423
Steuber T., Niemela P., Haese A., Pettersson K., Erbersdobler A., Felix Chun K.H., et al. Association of free-prostate specifie antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue Prostate 2005 ;  63 : 13-18 [cross-ref]
Partin A.W., Catalona W.J., Finlay J.A., Darte C., Tindall D.J., Young C.Y., et al. Use of human glandular kallikrein 2 for the detection of prostate cancer : preliminary analysis Urology 1999 ;  54 : 839-845 [inter-ref]
Becker C., Piironen T., Pettersson K., Hugosson J., Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater Urology 2000 ;  55 : 694-699 [inter-ref]
Mikolajczyk S.D., Grauer L.S., Millar L.S., Hill T.M., Kumar A., Rittenhouse H.G., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum Urology 1997 ;  50 : 710-714 [inter-ref]
Linton H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., Mikolajczyk S.D. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease Clin. Chem. 2003 ;  49 : 253-259 [cross-ref]
Canto E.I., Singh H., Shariat S.F., Lamb D.J., Mikolajczyk S.D., Linton H.J., et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer Urology 2004 ;  63 : 905-910 [inter-ref]
Oesterling J.E., Jacobsen S.J., Klee G.G., Pettersson K., Piironen T., Abrahamsson P.A., et al. Free, complexed and total serum prostate specifie antigen: the establishment of appropriate reference ranges for their concentrations and ratios J. Urol. 1995 ;  154 : 1090-1095 [cross-ref]






© 2007 
Elsevier Masson SAS. Tous droits réservés.